Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vopimetostat + daraxonrasib
- Development stage
- Phase 2
- Lead developer
- Tango Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vopimetostat + daraxonrasib is an investigational combination therapy co-developed by Tango Therapeutics and Revolution Medicines. Vopimetostat (TNG908) is an oral, once-daily, small molecule MTA-cooperative PRMT5 inhibitor that selectively targets cancer cells harboring MTAP (methylthioadenosine phosphorylase) deletions. Daraxonrasib (RMC-6236) is a RAS(ON) multi-selective inhibitor that targets oncogenic RAS mutations. The combination is designed to synergistically inhibit the RAS pathway and PRMT5 activity in MTAP-deleted, RAS-mutant tumors, such as pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Clinical data from Phase 1/2 trials have demonstrated high objective response rates and favorable progression-free survival in patients with metastatic PDAC.
- Other names
- TNG908 + RMC-6236
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)HRAS (H-Ras protein)
Beyond the preview
Go deeper on vopimetostat + daraxonrasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vopimetostat + daraxonrasib.